Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501639 · ClinicalTrials.gov registry record
Exacerbation Risk in Asthma
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,899
- Enrollment target
NCT05501639: Completed study, sponsored by Boehringer Ingelheim.
NCT05501639 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,899 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05501639 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,899 participants
- Enrollment target
Study Summary
The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
Primary Outcome
Severe exacerbation defined as: * Hospitalization with primary diagnosis of asthma or * Emergency room (ER) visit with primary diagnosis of asthma The analysis of this endpoint is based on number of observations (exacerbations). Index date is defined as date when patient entered the cohort. Design 1: A time-varying covariate approach to classify drug exposure time for each comparator drug during follow up was used. For each individual study drug, medication exposure + non-exposure windows duri
Interventions
- DRUG tiotropium
- DRUG long-acting β2-agonists (LABA)
- DRUG inhaled corticosteroids (ICS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,899 participants |
| Start Date | 2021-05-14 |
| Est. Completion | 2021-11-02 |
What the finished NCT05501639 record still lists
NCT05501639 is an observational study that tracks outcomes without assigning an intervention. Its 1,899 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which tiotropium is the first listed.
NCT05501639 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05501639 about?
NCT05501639 is a clinical study titled "Exacerbation Risk in Asthma". The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
What is the current status of trial NCT05501639?
This trial is currently completed. The enrollment target is 1,899 participants. The study started on 2021-05-14. Estimated completion is 2021-11-02.
What interventions are being tested in trial NCT05501639?
The interventions under investigation include: tiotropium (DRUG), long-acting β2-agonists (LABA) (DRUG), inhaled corticosteroids (ICS) (DRUG).
Who is sponsoring clinical trial NCT05501639?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI